1403584-89-3

Upstream product

• 1403584-85-9 (8S,9S)-14,14,15,15-tetramethyl-8-vinyl-2,5,7,13-tetraoxa-14-silahexadecan-9-ol 
• 1403584-86-0 (8S,9S)-14,14,15,15-tetramethyl-8-vinyl-2,5,7,13-tetraoxa-14-silahexadecan-9-one 
• 1403584-87-1 (8S,9R)-9,14,14,15,15-pentamethyl-8-vinyl-2,5,7,13-tetraoxa-14-silahexadecan-9-ol 

Downstream Products

• 1419687-24-3 (3R)-1-((S)-4-(tert-butyl)-2-thioxothiazolidin-3-yl)-3-((tert-butyldimethylsilyl)oxy)-5-((4R,5S)-2-(4-methoxyphenyl)-4-methyl-5-vinyl-1,3-dioxolan-4-yl)pentan-1-one 
• 1403584-90-6 (3R)-3-((tert-butyldimethylsilyl)oxy)-5-((4R,5S)-2-(4-methoxyphenyl)-4-methyl-5-vinyl-1,3-dioxolan-4-yl)pentanoic acid 
• 1403584-91-7 (3R)-(3S,4S,E)-1-iodo-2,4-dimethylhexa-1,5-dien-3-yl 3-((tert-butyldimethylsilyl)oxy)-5-((4R,5S)-2-(4-methoxyphenyl)-4-methyl-5-vinyl-1,3-dioxolan-4-yl)pentanoate 
• 1403584-96-2 (3R)-1-((S)-4-(tert-butyl)-2-thioxothiazolidin-3-yl)-3-hydroxy-5-((4R,5S)-2-(4-methoxyphenyl)-4-methyl-5-vinyl-1,3-dioxolan-4-yl)pentan-1-one 

Relevant academic research and scientific papers

Structure of FD-895 revealed through total synthesis

The total synthesis of FD-895 was completed through a strategy that featured the use of a tandem esterification ring-closing metathesis (RCM) process to construct the 12-membered macrolide and a modified Stille coupling to append the side chain. These stu

SCALEABLE PREPARATION OF POLYKETIDES

Disclosed herein, inter alia, are methods of making polyketide compounds.

ANTI-CANCER POLYKETIDE COMPOUNDS

Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.